Earnings call transcript: CTS Corp beats Q2 2025 earnings forecasts

CTS Corporation reported its second-quarter 2025 earnings, surpassing analyst expectations with an adjusted earnings per share (EPS) of $0.57 compared to the forecasted $0.55. Revenue also exceeded predictions, reaching $135.3 million against a forecast of $132.65 million. The positive results led to a 3.39% increase in CTS’s stock price, which closed at $40.44. According to InvestingPro analysis, CTS maintains a FAIR financial health score, with particularly strong profitability metrics. The company’s market capitalization stands at $1.25 billion, positioning it firmly in the mid-cap segment.

Key Takeaways

• CTS Corporation’s Q2 2025 earnings per share beat forecasts by 3.64%.
• Revenue for the quarter was $135 million, up 4% year-over-year.
• Stock price rose by 3.39% following the earnings announcement.
• The company continues to diversify into medical, industrial, aerospace, and defense markets.
• CTS maintains its full-year 2025 sales guidance between $520 million and $550 million.

Company Performance

CTS Corporation demonstrated robust performance in the second quarter of 2025, with a 4% year-over-year increase in sales. The company’s diversification strategy into various markets, including medical and industrial sectors, has contributed to its steady growth. Despite challenges in the transportation market, CTS’s focus on innovation and product development, such as the next-generation smart actuator, has bolstered its competitive position.

Financial Highlights

• Revenue: $135 million, a 4% increase from Q2 2024.
• Earnings per share: $0.57, up 30% sequentially and 7% year-over-year.
• Adjusted gross margin: 38.7%, an increase of 296 basis points from 2024.
• Operating cash flow: $28 million, compared to $20 million in Q2 2024.

Earnings vs. Forecast

CTS Corporation’s Q2 2025 EPS of $0.57 surpassed the forecasted $0.55, marking a positive surprise of 3.64%. Revenue also exceeded expectations, coming in at $135.3 million against a forecast of $132.65 million, a 2% surprise. This performance highlights the company’s ability to deliver above market expectations, continuing a trend of beating forecasts.

Market Reaction

Following the earnings report, CTS’s stock price increased by 3.39% to $40.44, reflecting positive investor sentiment. This movement places the stock closer to its 52-week high of $59.68, indicating renewed confidence in the company’s growth prospects. Based on comprehensive InvestingPro Fair Value analysis, CTS currently appears fairly valued, trading at a P/E ratio of 20.57. The market’s reaction aligns with broader sector trends, where companies exceeding earnings expectations have seen favorable stock performance. Discover detailed valuation metrics and 1,400+ comprehensive Pro Research Reports available on InvestingPro.

Outlook & Guidance

CTS Corporation reaffirmed its 2025 sales guidance of $520 million to $550 million and adjusted diluted EPS guidance of $2.20 to $2.35. The company anticipates improved revenues in the latter half of 2025, driven by its strategic initiatives and product innovations. However, it remains vigilant about potential headwinds from trade tariffs and geopolitical uncertainties.

Executive Commentary

CEO Kieran O’Sullivan emphasized the importance of diversification, stating, "Diversification remains a strategic priority." He also highlighted the launch of the "Evolution 2030" strategic initiative, aimed at enhancing sales growth and operational rigor. CFO Ashish noted the impact of government funding patterns on SideQuest’s sales seasonality.

Risks and Challenges

• Potential impact of trade tariffs and geopolitical tensions on supply chains.
• Softening electric vehicle penetration rates in certain regions.
• Market volatility in the transportation sector.
• Dependence on successful integration of acquisitions like SideQuest.

Q&A

During the earnings call, analysts inquired about the medical market’s performance, noting a 60% increase in therapeutic sales despite softness in diagnostics. Questions also focused on the minimal impact of tariffs in Q2 and the mixed performance across different regions in the transportation market. Executives reiterated their focus on potential acquisitions to further diversify revenue streams.

Full transcript - CTS Corp (CTS) Q2 2025:

Operator: Good morning or good afternoon all, and welcome to the CTS Corporation Second Quarter twenty twenty ’5 Earnings Call. My name is Adam and I’ll be your operator for today. I will now hand the floor to Kieran O’Sullivan, Chairman, President and CEO to begin. So, Kieran, please go ahead when you’re ready.

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Good morning and thank you for joining us today for our second quarter twenty twenty five results. We delivered another quarter of double digit growth in our diversified end markets. Diversified sales for the quarter were 55% of overall company revenue. In the quarter, our adjusted EBITDA expanded two fifty basis points sequentially 130 basis points compared to the second quarter of last year. Cash flow generation was also strong in the quarter.

Our teams continue to execute on our diversification strategy to increase growth in diversified medical, industrial, aerospace and defense markets. In transportation, we launched the next generation smart actuator for the commercial vehicle market. Ashish will take us through the safe harbor statement. Ashish?

Ashish, CFO or Financial Officer, CTS Corporation: I would like to remind our listeners that this conference call contains forward looking statements. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed in the forward looking statements. Additional information regarding these risks and uncertainties is contained in the press release issued today and more information can be found in the company’s SEC filings. To the extent that today’s discussion refers to any non GAAP measures under Regulation G, the required explanations and reconciliations are available with today’s earnings press release and supplemental slide presentation, which can be found in the Investors section of the CTS website. I will now turn the discussion back over to our CEO, Kirin O’Sullivan.

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Thank you, Ashish. We finished the second quarter with sales of $135,000,000 up 4% from $130,000,000 in the second quarter of twenty twenty five. For the quarter diversified end market sales including sales to medical, aerospace and defense and industrial end markets were up 13% driven by a mix of organic growth and the Sighwest acquisition. Transportation sales were down 6% from the same period last year. Diversified end market sales were 55% of overall company revenue in the quarter.

Our book to bill ratio for the second quarter was one, essentially flat in comparison to the second quarter of twenty twenty four. Bookings for our diversified end markets were down in Medical due to larger bookings earlier this year. Defense bookings were flat while Industrial bookings were up 22%. Second quarter adjusted diluted earnings were $0.57 per share, up approximately 30% from the first quarter and up 7% from the prior year period. Ashish will add further color on our financial performance later in today’s call.

In the medical end market, second quarter sales were up eight percent compared to the same period in 2024. We are excited about the prospects for growth in minimally invasive applications where our products help deliver enhanced ultrasound images, making it easier for medical professionals to detect artery restrictions and deliver treatment medications. Our teams are engaged on next generation development engineering to further enhance diagnostic capability with our customers. We are proud to highlight our product support solutions that help save lives. During the second quarter, we had wins for medical ultrasound across all regions and an award for a pacemaker application.

In addition, we added a new customer for an ultrasound application. Demand for therapeutic products were up approximately 60% year over year. Bookings in the quarter were down 10% compared to the prior year period due to softness in diagnostic bookings. Over time we expect the volume increases in portable ultrasound diagnostics and therapeutics will continue to enhance our growth profile. Aerospace and Defense sales for the second quarter were up 34% from the second quarter of twenty twenty four.

Excluding sales from the SideQuest acquisition, sales were up 6%. SideQuest revenues in the second quarter were $4,500,000 and we expect stronger sales in the second half of this year. Bookings in the second quarter were flat from the prior year period as we maintain a healthy backlog. Our strategy is focused on moving from a component supplier to a supplier of sensors, transducers and subsystems. We received multiple orders in the quarter for sonar transducers across North America and Europe, transducer refurbishments and outboard electronic applications.

The integration of the SiQuest business is progressing and the business continued to drive a strong pipeline of opportunities. In the industrial market, we continue to see a gradual recovery with OEMs as well as with distribution customers. Sales in the second quarter were up 5% sequentially and up 6% compared to the prior year period underscoring our expectation of a continued recovery. Bookings in the quarter were up 22% from the same period last year. We were successful with multiple wins in the quarter for EMC, switches, industrial printing and temperature sensing applications where we won a new business award for EV charging stations in Europe.

We added a new customer in the quarter for a millimeter wave small cell frequency application. Demand across the industrial market is expected to continue improving in the second half of twenty twenty five. The megatrends of automation, connectivity and efficiency enhance our longer term growth prospects. Transportation sales were €61,000,000 in the second quarter, down approximately 6% from the same period last year due to the impacts of China market dynamics and softness for commercial vehicle products. In the second quarter, we had awards across various product groups including accelerator module wins with customers in North America, Europe and Asia.

Additionally, we received the chassis ride height sensing award from a North American OEM. More recently on the innovation front, we advanced our Cobras technology, which enables precise position sensing with high resolution for motor position sensing. The near term growth rates for ICE versus EVs and hybrids are less of a concern for us given our light vehicle products are mostly agnostic to the drivetrain technology. Total booked business was approximately £1,000,000,000 at the end of the quarter. Interest in our e brake product offering weight and cost advantages continues across OEMs at a slower pace as certain OEMs recalibrate EV investments.

Our team is proceeding with samples and design customizations for OEMs and Tier 1s. We remain confident in the longer term growth prospects for this product line given the cost and weight benefits for our customers as well as the sentiment in the market from OEMs and Tier one chassis system suppliers. We expect our e brake, other footwell products, existing and new sensor applications will increase our ability to grow content. For our diversified end markets in line with our strategy, we aim to expand the customer base and range of applications. Subject to evolving trade tariffs and associated economic uncertainty, demand in the medical end market is expected to be mixed with strength in therapeutics and some softness in diagnostic ultrasound.

In Aerospace and Defense, revenue is expected to grow given our backlog of orders and momentum from the SightQuest acquisition. Industrial and distribution sales are expected to improve. Longer term, we expect our material formulations supported by three leading technologies and their derivatives to continue to drive our growth in key high quality end markets in line with our diversification strategy. Across transportation markets, production volumes are expected to decrease in 2025 given the tariff impact and the supply of rare earth for OEMs and Tier one suppliers. The North American light vehicle market is expected to be in the 15,000,000 unit range.

European production is forecasted in the 16,000,000 unit range and showing some increased softness due to pressure from Chinese OEMs. China volumes are expected to be in the 30,000,000 unit range. Electric vehicle penetration rates have softened in some regions, while hybrid adoption continues to improve. More recently, our next generation commercial vehicle actuator commenced low volume production during the quarter. Overall, we are monitoring the potential for headwinds in transportation revenue due to trade tariffs and the China market dynamics.

We anticipate softness in commercial vehicle related revenue for the remainder of the year. As I mentioned in previous calls, revenue from the SideQuest acquisition will introduce some seasonality where the timing of revenue may be influenced by the approval of funding by the U. S. Government. With the recent budget approval, we expect revenues for cycles to improve in the second half of twenty twenty five.

The impact of tariffs and the geopolitical environment are creating uncertainty. We continue to closely monitor and evaluate the situation while focusing on agility and adapting to cost and price adjustments in close collaboration with our customers and suppliers. Assuming the continuation of current market conditions, we are maintaining our guidance of sales in the range of $520,000,000 to €550,000,000 and adjusted diluted EPS to be in the range of $2.2 to $2.35 Now I’ll turn it over to Ashish who will walk us through the financial results in more details. Ashish?

Ashish, CFO or Financial Officer, CTS Corporation: Thank you, Kieran. Sales in the second quarter were $135,000,000 up 8% sequentially and up 4% from the last year. Sales to diversified end markets increased 13% year over year. CyQuest added $4,500,000 in revenue during the quarter. As Kieran has highlighted, we are seeing seasonality in sales from Syquest due to government funding patterns and expect a stronger second half.

Sales to transportation customers were down 6% from the second quarter of last year due to softness in sales related to commercial vehicle products and reduced volumes due to China market dynamics. Our adjusted gross margin was 38.7% in the second quarter, up two ninety six basis points compared to the 2024 and up 174 basis points sequentially compared to the first quarter of twenty twenty five. As we continue to work on diversification as a strategic priority, we are seeing a favorable mix impact on our profitability. In addition, our global teams continue to focus on operational execution to deliver margin improvements. We are working closely with customers and suppliers on tariffs and had a minimal impact on profitability in the second quarter.

Exchange rate changes had a favorable impact of $1,000,000 on gross margin. We achieved adjusted EBITDA of 23% in the quarter, an improvement of two fifty basis points sequentially and 130 basis points compared to the second quarter of twenty twenty four. Earnings were $0.62 per diluted share for the second quarter. Adjusted earnings were $0.57 per diluted share compared to $0.44 in the 2025 and $0.54 in the second quarter of twenty twenty four. Moving to cash generation and the balance sheet.

We generated $28,000,000 in operating cash flow in the second quarter compared to $20,000,000 in the second quarter of twenty twenty four. Year to date, we have generated $44,000,000 in operating cash flow. Our balance sheet remains strong with a cash balance of $99,000,000 at the end of the quarter. Our long term debt balance was $88,000,000 leaving us good liquidity to support strategic acquisitions. During the quarter, we repurchased 412,000 shares of CTS stock for approximately $17,000,000 In total, we returned $26,000,000 to shareholders through dividends and share buybacks so far in 2025.

We have $38,000,000 remaining under our current share repurchase program. Our focus remains on strong cash generation and appropriate capital allocation and we continue to support organic growth, strategic acquisitions and returning cash to shareholders. This concludes our prepared comments. We would like to open the line for questions at this time.

Operator: And our first question today comes from John Franzreb from Sidoti.

Ashish, CFO or Financial Officer, CTS Corporation: John, please go ahead. Your line is open.

John Franzreb, Analyst, Sidoti: Good morning, everyone, and thanks for taking the questions. Kieran, I’d like to start with the medical market. It seems like there’s maybe two different product lines going two different directions. Therapeutics, you said, was up 60%, I believe. But also I think you issued a little bit of a warning about diagnostics.

Can you talk a little bit about what’s going on in the marketplace there for you?

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Yes, John. On the therapeutic side on the last earnings call we talked about a larger order and that’s obviously playing out here in the second quarter and for the balance of the year as well. We’ve seen some softness in diagnostics on the ultrasound side of it mostly coming from capital spend in Asia and maybe tariff related as well. So we will see some softness there. But overall on medical for the year we will see growth.

John Franzreb, Analyst, Sidoti: Good. That’s good to hear. And you just touched on the tariff situation. What was the impact, if any, of tariffs, on you in the quarter?

Ashish, CFO or Financial Officer, CTS Corporation: It was pretty nominal, John. As we mentioned in the prepared remarks, we are working closely with customers as well as suppliers. Overall, the impact very, very minimal in the quarter.

John Franzreb, Analyst, Sidoti: Do you expect it to stay that way?

Ashish, CFO or Financial Officer, CTS Corporation: Generally, under the current conditions, would say yes. But there’s a lot of changes happening as you know. So we are continuing to monitor the situation. As we have talked about in the past, our bigger impact happens with any potential changes in The U. S.

And CA.

John Franzreb, Analyst, Sidoti: Okay. Got it. And when you think about the transportation market, Kieran, you’re also signaling continued weakness. Any thoughts about when that market might bottom out for you?

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: John, obviously, yes, weakness this year. It’s mixed across the regions. We’ve talked about softness in China being a factor for us in the commercial vehicle. We think it’s bottomed out in China, but we’re being a little bit just cautious on that. So we see the trend over a few quarters.

On the light vehicle side, we did improve sequentially this quarter. And I would tell you we’ve got a pipeline of booked businesses really strong across multiple products that we’re working. So it’s a little bit mixed, John. I would just say the tariff situation is the one we’re watching there. There was some pre buy in Q2 in April and May.

It just feels a little tenuous for the next few quarters.

John Franzreb, Analyst, Sidoti: Makes sense. And just on the cost side of the equation, how is the integration of SciQuest going? Is that fully complete? And are there other cost measures you’re currently active on outside of that?

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: John, the SideQuest acquisition is moving along well. A lot of the integration work has been done. And there’s still a little bit more to do and we’re still running on different ERP systems. But the pipeline of opportunities is really strong. What I would tell you is the timing with the government and getting the budget approval has been something we’ve been watching carefully and glad to see that approved because we think that’s going to be a momentum builder going forward.

John Franzreb, Analyst, Sidoti: Okay. And any other internal cost saving actions that you’re currently executing?

Ashish, CFO or Financial Officer, CTS Corporation: So on Cyquest, John, we are really not looking to drive cost saving type of actions. The business is working on a strong pipeline, and we are shoring up capabilities from a production standpoint to make sure that we can, drive that growth and, do the revenue growth part of it, more strongly in that part of it.

John Franzreb, Analyst, Sidoti: Understood, Ashish. Was actually referencing legacy CTS.

Ashish, CFO or Financial Officer, CTS Corporation: Got it. Got it. So in terms of we are continuing to look at operational efficiency on an ongoing basis like we always do, John. That was contributing to our gross margin expansion in the quarter that we talked about. But in terms of big things that we have in the works, there’s not much that we have talked about publicly.

As we continue working on things, if there are bigger changes we are making, I’m sure we’ll highlight those.

John Franzreb, Analyst, Sidoti: Great. Okay. I’ll get back in queue. Thanks for taking my questions.

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Thanks, John.

Operator: The next question comes from Hendi Susanto from Gabelli Funds.

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Hendi, your

Ashish, CFO or Financial Officer, CTS Corporation: line is open. Please go ahead.

Hendi Susanto, Analyst, Gabelli Funds: Good morning, Kieran and Ashish.

Ashish, CFO or Financial Officer, CTS Corporation: Good morning, Hendi. Hi, Hendi.

Hendi Susanto, Analyst, Gabelli Funds: Kieran and Ashish, I would like to ask to ask like similar questions, but hopefully deeper. The mix dynamic in medical marketplace, like in diagnostic and then in therapeutic, Any guideposts on, let’s say, how much the large order would sustain or generate a nice revenue upside in the next coming quarters? And then on the other hand the softness in diagnostic like how much further should we expect?

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Hendi, the softness in diagnostics maybe for a quarter or two. We still feel very confident in the growth of that business in the mid to long term. On the therapeutic side, confident in the growth throughout the balance of this year and then we would expect new purchase orders as we go ahead. So overall, as I mentioned earlier, we’ll see growth in Medical this year and we’re expecting growth as we go into the years ahead too.

Hendi Susanto, Analyst, Gabelli Funds: Okay. Got it. And then Asis, may I ask how much revenue SaiQuest generated in the same quarter a year ago so that we know on a year over year comparison what the numbers look like?

Ashish, CFO or Financial Officer, CTS Corporation: Yes. Hendi, we closed on the acquisition towards the July. So the 2025 was purely additive.

Hendi Susanto, Analyst, Gabelli Funds: Yes. But can we know prior to acquisitions, like how much the quarterly revenue in the second quarter of twenty twenty four?

Ashish, CFO or Financial Officer, CTS Corporation: We haven’t talked about that, Hendi, in terms of pre acquisition revenues. So that’s something that we haven’t talked about publicly.

Hendi Susanto, Analyst, Gabelli Funds: Yeah. And then I think I asked like similar question in the past within transportation. How much is China?

Ashish, CFO or Financial Officer, CTS Corporation: China transportation as a percent of our overall revenue will be similar to what we have for the overall transportation as a percent of total CTS, that’ll give you get you close enough in terms of how much revenue we have in China. When you look at overall China, we our last year’s data that was published as part of the 10 ks, we had revenues of about $80 plus million in total.

Hendi Susanto, Analyst, Gabelli Funds: Okay. Got it. And then Kieran, you talk about a strong pipeline of opportunities. Sorry, I think you said that in transportation, there are some solid like positive pipelines across products that you are working on. Would you be able to mention which products can Yes.

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Hendi, we would be working with customers on accelerator modules, passive safety sensors, new combination sensors, motor position sensing. Just to give you a few examples in transportation. And we also have a strong pipeline in the diversified end markets as well.

Hendi Susanto, Analyst, Gabelli Funds: And then within the transportation, those pipelines, are they more skewed toward North America and Europe?

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Hendi, I would certainly we’ve been winning business in all regions. I would say the larger pipeline is in the North America region for sure. But some of these OEMs are operating globally too.

Hendi Susanto, Analyst, Gabelli Funds: Okay. Got it. Yes. Okay. Thank you.

Let me get back to the queue.

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Thank you, Henry. Thank

Ashish, CFO or Financial Officer, CTS Corporation: you.

Operator: You return to the line from John from Sidoti. John, please go ahead.

John Franzreb, Analyst, Sidoti: Yes. Just a follow-up question. Can you talk a little bit about the acquisition market, what you’re seeing out there, maybe the size of the opportunities that you’re most focused on?

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: John, we’re most focused on advancing our diversified end markets that be aerospace and defense, industrial and medical. There’s we’re always working on a pipeline of opportunities. There’s nothing to report at this point in time. But we certainly see some uptick in activity out there.

John Franzreb, Analyst, Sidoti: That’s great. Something maybe within the next twelve months or am I thinking too far ahead?

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Well John, if you look at how we talk about our growth 5% organic 5% through acquisitions we would definitely like to do something in the next twelve months.

John Franzreb, Analyst, Sidoti: All right. Good to hear. Thanks for taking my follow-up.

Operator: Thank you, John.

Ashish, CFO or Financial Officer, CTS Corporation: Thank you.

Operator: We have no further questions. So I’ll hand the call back to Kieran for some closing comments.

Kieran O’Sullivan, Chairman, President and CEO, CTS Corporation: Thanks, Adam, and thank you all for your time today. Despite the challenges of tariffs, geopolitical and economic pressures diversification remains a strategic priority. We launched our Evolution 2030 strategic initiative to enhance our emphasis on sales growth, operational rigor and employee engagement while also giving back to the communities where we operate. We look forward to updating you on our third quarter twenty twenty five performance in October. This concludes our call.

Thank you.

Operator: This concludes today’s call. Thank you very much for your attendance. You may now disconnect your lines.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.